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Dose related pharmacokinetics of ofloxacin in
healthy volunteers
C. Immanuel, A. K. Hemanthkumar, P. Gurumurthy, P. Venkatesan
S U M M A R Y
Tuberculosis Research Centre (ICMR), Chennai, India
OBJECTIVE: To evaluate the pharmacokinetic profile of
ofloxacin in healthy volunteers after single oral doses of
600 and 800 mg.
DESIGN: Seven healthy volunteers were administered
600 and 800 mg of ofloxacin on two occasions with an
interval of one week. Paired samples of blood and saliva
were collected after 1, 2, 3, 6, 9, 12, 24, 32 and 48 hours
post-dose. Urine samples were collected over a period of
0–6, 6–12 and 12–24 hours. Concentrations of ofloxa-
cin in plasma, saliva and urine were assayed by high per-
formance liquid chromatography.
RESULTS: Increases of 22% in peak plasma concentra-
tion (Cmax) and 40% in area under the concentration-
time curve (AUC0–24) were observed with the 800 mg
dose. The other parameters, namely time to attain Cmax,
half-life, the apparent volume of distribution, plasma
and renal clearance and percentage of dose excreted in
urine over 24 hours were independent of doses. The
mean ratios of the concentration in saliva to the concen-
tration in plasma ranged from 0.4–0.6, and the correla-
tion coefficient was 0.94.
CONCLUSIONS: Dose proportionality was observed in
Cmax and AUC0–24 when 600 and 800 mg doses of oflox-
acin were given. Ofloxacin determined in saliva seems to
be suitable for therapeutic drug monitoring.
KEY WORDS: pharmacokinetics; saliva to serum concen-
tration ratio; urinary excretion; ofloxacin; tuberculosis
THE FLUOROQUINOLONES are the most recent
class of drugs to offer hope in the treatment of tuber-
culosis. Among the quinolones, the drug most com-
monly used against Mycobacterium tuberculosis is
ofloxacin (OFX). Ofloxacin has high antibacterial
activity against gram-positive and gram-negative bac-
teria in vitro and in vivo, and it has shown good anti-
tuberculosis activity under in vitro conditions.1 It is as
useful as ethambutol in the treatment of pulmonary
tuberculosis when either drug is combined with iso-
niazid and rifampicin.2 The other important findings
related to OFX include its effectiveness in the retreat-
ment of patients with multidrug-resistant tuberculo-
sis (MDR-TB) who have failed on retreatment with
rifabutin, and its superior activity at higher doses.3,4
In vitro studies on bactericidal activity against M.
tuberculosis have suggested that OFX is likely to be
most useful in the early stages of treatment and in pre-
venting the emergence of resistance to other drugs.5
A multicentre study of the early bactericidal activity
(EBA) of anti-tuberculosis drugs showed a moder-
ately high mean EBA for OFX, ranging from 0.130 to
0.391.6
In a recent controlled clinical trial undertaken at
the Tuberculosis Research Centre (TRC), Chennai,
India, the efficacy of a daily regimen of 3–5 months’
duration, using OFX as one of four drugs in the inten-
sive phase, was studied in the treatment of patients
with smear-positive pulmonary tuberculosis. The re-
sults indicated greater than 95% efficacy, with no
increased incidence of adverse reaction and minimal
relapses.7 The encouraging results of this trial led us
to study its efficacy in intermittent regimens. Intermit-
tent regimens have several potential advantages of
facilitating fully supervised drug administration as
well as reducing drug costs and toxicity.8 Monitoring
of OFX concentrations in body fluids is beneficial in
assuring that maximum peak concentration (Cmax) to
minimal inhibitory concentration (MIC) ratios are
being achieved.1 This information may be valuable to
guide chemotherapy, as good antimicrobial activity
against M. tuberculosis is associated with pharmaco-
dynamic values calculated on the basis of Cmax/MIC
and area under concentration-time curve (AUC)/MIC
ratios.
The purpose of the present study was to determine
the pharmacokinetic parameters of OFX in healthy
volunteers after administration of single oral doses of
600 and 800 mg. Ofloxacin concentrations were mon-
itored simultaneously in blood and saliva to examine
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whether the concentration of this drug in saliva can
replace plasma for therapeutic monitoring. The uri-
nary excretion of OFX was also studied. There are
limited data in the literature of the oral pharmacoki-
netics of 600 mg OFX in volunteers,9–11 and none for
800 mg.
MATERIALS AND METHODS
Study design
Seven healthy male volunteers with a mean age of
34.5 years (range 22–50 years) and a mean body
weight of 59.2 kg (range 44–78 kg) participated in
the study. The volunteers were determined to be
healthy on the basis of medical history and hepatic
and renal function tests. The study protocol was
approved by the institutional ethics committee, and
informed written consent was obtained from all the
volunteers. After an overnight fast, 600 mg of OFX
(FDC Ltd., Goa, India) was administered orally to all
the volunteers on the first occasion; after a washout
period of 1 week, 800 mg of OFX was given on the
second occasion to the same volunteers. The exact
content of the drug in the lots used was determined
spectrophotometrically, and the results were found to
be within the acceptable limits of 5%.
Sampling
Paired samples of heparinised blood and saliva were
collected at 1, 2, 3, 6, 9, 12, 24, 32 and 48 hours
after oral administration of OFX. Saliva was col-
lected after rinsing the mouth with water before
starting and with the help of unsweetened chewing
gum. Blood specimens were centrifuged immediately
and plasma separated and stored at 20C. Saliva
samples were frozen at 20C; they were thawed the
next day, centrifuged and the supernatant stored at
20C until assay. Urine samples were collected
from 0–6, 6–12 and 12–24 hours after dosing. The
volume was measured and an aliquot was stored at
20C until assay.
Assay of ofloxacin
Ofloxacin concentrations in plasma, saliva and urine
were determined by high performance liquid chroma-
tography (HPLC) according to the method of Imman-
uel and Hemanth Kumar.12 The Shimadzu HPLC sys-
tem used (Shimadzu Corporation, Kyoto, Japan) was
equipped with two pumps (LC-10ATvp), a spectro-
fluorometric detector (RF-10AXL) and a system con-
troller (SCL-10Avp). A rheodyne manual injector
(Rheodyne, Cotati, CA, USA) attached with a 20 L
sample loop was used for loading the sample. Briefly,
the method consisted of the separation by a reverse-
phase column and fluorescence detection. The mobile
phase consisted of 50 mM phosphate buffer (pH 2.6
adjusted with 1.5 M disodium hydrogen phosphate)-
acetonitrile (82:18 v/v). A C18 5  Luna, 250  4.6
mm ID (Phenomenex, Torrance, CA, USA) reverse-
phase column with a matched guard column was used
for the assay. Plasma was deproteinised with 7% per-
chloric acid and the supernatant injected. Saliva was
centrifuged in the microcentrifuge filters (Millipore,
Tokyo, Japan) and the filtrate was injected. The urine
samples were appropriately diluted in MilliQ water
followed by direct injection. The fluorescence detec-
tor was operated under the following conditions:
excitation 290 nm, emission 460 nm; the sensitivity
ranges for plasma and saliva assays were set at low
combined with gain of 4 and for the urine assay it
was set at low 1. Under these conditions, the assay
was linear from 0.1–10 mg/L for all the body fluids.
The coefficient of variations for the within-day and
between-day performance were lower than 5%.
Plasma standards for the calibration graph were
prepared by using blood bank plasma. The saliva stan-
dards were prepared in pooled human saliva passed
through the microcentrifuge filters. There was no
non-specific binding in the membrane of the filters,
and the recovery was 100%. Urine standards were
prepared in pooled human urine diluted with Milli-Q
water. The chromatogram was run for 7 minutes at a
flow rate of 1.5 ml/min. The retention time for OFX
was 5 minutes.
Pharmacokinetic analysis
Maximum concentrations (Cmax) and the time to
attain Cmax (Tmax) were determined by direct visual
inspection of data. Ofloxacin concentration–time
data were analysed by a non-compartmental model
using WinNonlin software (Pharsight Corp, Moun-
tain View, CA, USA). The linear trapezoidal rule was
used to compute the AUC; the elimination rate con-
stant (Kel) was calculated from the terminal log-linear
decline of concentration; the terminal elimination
half-life (t1/2) was calculated as 0.693/Kel; and AUC0–
was calculated by adding the sum of AUCs obtained
from time zero until 32 h concentration to the last
quantifiable concentration (at 32 h) divided by Kel.
The apparent volume of distribution (Voral) was calcu-
lated as dose/(AUC0–  Kel) and plasma clearance
(CLtot) as dose/AUC0–. The amount of unchanged
OFX excreted in the urine at 24 h (Ae24) was calcu-
lated as the product of urine volume and OFX con-
centration in urine. The percentage was calculated as
(Ae24/dose)  100. The renal clearance (CLR) of OFX
was calculated as Ae24/AUC0–24.
Statistical evaluation
Data were expressed as mean with 95% confidence
intervals (CI). The significance of differences in the
pharmacokinetic parameters between doses was eval-
uated by using Student’s paired t-test. A P value of
0.05 was considered statistically significant. Corre-
lation between plasma and salivary concentrations of
OFX was assessed by linear least-squares regression
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analysis by plotting the plasma concentrations against
those of saliva at all time points for both doses (n 	 126).
RESULTS
The mean dosage was 11.9 mg/kg (range 7.7–13.8)
for the 600 mg dose and 15.8 mg/kg (range 10.3–
18.3) for the 800 mg dose of OFX. Mean concentra-
tions of OFX in plasma at different time points after
600 and 800 mg of doses are depicted in Figure 1. The
higher dose of 800 mg resulted in higher concentra-
tions at all time points except at 1 hour. The differ-
ences were statistically significant (P 
 0.05). The
mean trough levels for thrice weekly dosage (48
hours) were 0.10 mg/L for the 600 and 0.13 mg/L for
the 800 mg doses.
The pharmacokinetic parameters calculated on the
basis of plasma and urine concentrations for the 600
and 800 mg doses are given in Table 1. The mean
Cmax was 8.0 mg/L for the 600 mg and 9.8 mg/L for
the 800 mg dose (P 	 0.03). With an increase in dose,
the Tmax was slightly longer, but not statistically sig-
nificantly so. There were no changes in the apparent
volume of distribution and half-life between the
doses. The mean AUC0–24 was 60.8 and 85.8 mg.h/L
for 600 and 800 mg, respectively (P 	 0.02). The
mean plasma clearance was 156 ml/min for the 600 mg
and 151 ml/min for the 800 mg doses. Renal clearance
accounted for 68% and 61% of the corresponding
plasma clearances for the 600 and 800 mg doses, respec-
tively. The proportion (%) of dose excreted in urine
over a 24-hour period seemed to be slightly lower for
the higher dose, but this difference was not significant
(62% and 57% for 600 and 800 mg, respectively).
The OFX concentrations in saliva were much lower
than those in plasma, as corresponding Cmax values
were 4.1 and 8.0 mg/L for the 600 mg dose and 4.2
and 9.8 mg/L for the 800 mg dose, respectively. The
ratios of OFX concentration in saliva to plasma were
calculated for all time points (Figure 2). The results
showed that the ratios ranged from 0.40 to 0.57 for the
600 mg and from 0.40 to 0.56 for the 800 mg dose.
The correlation coefficient between plasma and saliva
concentrations was 0.94. The mean saliva AUC0–24
was 29.7 mg.h/L for 600 mg and 40.2 mg.h/L for 800
mg (48% of the plasma AUC0–24 for both doses).
DISCUSSION
The dosage of OFX used to treat tuberculosis varied.
Once-daily administration of this drug is possible, as
Figure 1 Mean plasma concentrations following administra-
tion of 600 and 800 mg of OFX in seven healthy volunteers.
Table 1 Pharmacokinetic parameters for OFX in seven healthy volunteers
600 mg 800 mg
Parameters Mean (95%CI) CV % Mean (95%CI) CV %
Cmax (mg/L) 8.0 (7.4–8.6) 11 9.8 (8.2–11.4) 22
Tmax (h) 1.4 (1.0–1.8) 37 1.9 (1.6–2.2) 20
Voral (L) 86 (78–94) 13 83 (72–94) 18
T1/2 (h) 6.7 (6.2–7.2) 11 6.5 (6.1–6.9) 8
AUC0–24 (mg.h/L) 60.8 (54.2–67.4) 13 85.3 (69.4–101.2) 23
AUC0– (mg.h/L) 67.9 (60.9–74.9) 14 93.1 (79.7–106.5) 19
CLtot (ml/min) 149 (135–163) 12 147 (128–166) 18
CLR (ml/min) 105 (88–122) 22 92 (74–110) 26
Ae24 (%) 63 (56–69) 14 57 (52–61) 10
CI 	 confidence interval; CV 	 coefficient of variation; Cmax 	 maximum concentration; Tmax 	 time to attain Cmax;
Voral 	 volume of distribution; T1/2 	 terminal elimination half-life; AUC 	 area under the concentration-time curve;
CLtot 	 total plasma clearance; CLR 	 renal clearance; Ae24 	 amount of unchanged OFX excreted in the urine at
24 h.
Figure 2 Mean saliva to plasma OFX concentration ratios
after the administration of 600 and 800 mg.
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the generation time of M. tuberculosis is 24 hours.1 In
the controlled clinical trial undertaken at the TRC,
600 mg of OFX was given daily along with isoniazid,
rifampicin and pyrazinamide to patients with a body
weight of more than 40 kg.7 Other authors have used
up to 800 mg of OFX once daily.4 The present study
was performed to obtain information on the pharma-
cokinetic profile when 600 and 800 mg of OFX were
given orally.
The pharmacokinetics of OFX displayed a 22%
increase in the Cmax and a 40% increase in the AUC
with the 800 mg dose compared to the 600 mg dose.
This study also demonstrated that inter-individual
differences in these parameters were greater for the
800 mg dose, with Cmax values ranging from 8 to 13
mg/L (CV 22%) and AUC0–24 values ranging from
64.7 to 126.5 mg.h/L (CV 23%). The highest values
in both the parameters were recorded in the volunteer
with the lowest body weight (43.6 kg), with a dosage
of 18.3 mg/kg. These values were reflected in both
plasma and renal clearance, which were lowest in this
volunteer.
The lack of difference in renal clearance between
doses implies that the secretory process has not been
saturated. Our finding of urinary excretion indepen-
dent of doses is also corroborated by other studies
where oral administration of 100, 300 and 600 mg of
OFX resulted in 70% excretion.9 Dose proportional-
ity was observed in Cmax and AUC for 600 and 800 mg
doses when compared with lower dose.11 The appar-
ent volume of distribution was dose-independent,
consistent with other findings.9–11
Use of saliva instead of blood for pharmacokinetic
investigations has obvious practical advantages. It is a
non-invasive procedure, which avoids venipuncture,
and is therefore more suitable for the collection of
multiple specimens. Pharmacokinetic studies have
shown that OFX penetrates into saliva and that its
concentration correlates well with serum levels.13
However, the data available in the published studies
are inconsistent. Variable results have been reported
for the ratio of saliva to serum concentrations. Koi-
zumi et al. reported a ratio of 1.0 between 2 and 8
hours after administration of a 300 mg dose.14 Fujita
et al. in their studies on patients with renal impair-
ment reported a 1:1 ratio of saliva to serum concen-
trations.15 However, Warlich et al. reported a ratio of
0.6 and a close relation of levels in saliva and serum
(r 	 0.99).16 These results are consistent with our
findings. In the present study the ratio was around
0.5, Tmax and half-life were similar to plasma, and
there was a good correlation coefficient of 0.94 with
respect to drug concentrations. OFX determination
in saliva therefore seems to be suitable for therapeutic
drug monitoring.
From the published data, it can be inferred that the
clinical response to OFX appears to be dose-related.
The drug is most effective when the Cmax to MIC and
or AUC to MIC ratios are maximised.1 The MIC90
value of OFX against M. tuberculosis is 1.0 mg/L.17–19
The pharmacodynamic parameters calculated on the
basis of the AUC could be useful for predicting
the efficacy of a drug. In the present study, the AUC to
MIC ratio for 800 mg dose was significantly higher
than that with the 600 mg dose. The coverage, i.e.,
the time above the level of MIC, was 24 hours for 800
mg as against 20 hours for the 600 mg dose (Table 2).
These results are in agreement with the recent study
by Zhu et al., who reported simulated pharmaco-
kinetic (PK)/pharmacodynamic (PD) estimates for 600
and 800 mg doses of OFX in tuberculosis patients.20
Another putative pharmacodynamic parameter that
could be of help in the design of an optimal dosing
schedule is the post antibiotic effect (PAE) of a drug
against M. tuberculosis. Studies on OFX tested at a Cmax
value of 8 mg/L suggested the use of OFX daily, but it
could have synergistic activity when given in combina-
tion with rifampicin.21 Hence, the recommendation was
that it should be given intermittently only when rifampi-
cin is included in the regimen. The extended period of
coverage and the higher ratio of AUC to MIC for the
800 mg dose could be beneficial for intermittent che-
motherapy. Clearance is not affected be-cause of the
higher dose. However, it was observed that subjects
weighing 
50 kg when given 600 mg attained an
AUC similar to that of 800 mg given to the subjects
weighing 50 kg. Therefore, the dosage for intermit-
tent therapy may be adjusted accordingly.
The limitation of this study was the participation
of a small number of volunteers. However, the infor-
mation is still valid because the same volunteers were
given both doses.
Pharmacokinetic knowledge about a drug enables
the clinician to choose the dosage schedule, the opti-
mal size and the frequency of individual doses. The
use of the AUC is particularly appropriate because it
provides an integral measure of drug exposure and
therefore an individual indicator of the therapeutic
value of the drug. We must, however, understand the
assumptions on which it relies; the pharmacokinetic
parameters must therefore be interpreted by relating
the concentration-time profile to clinically important
end-points. The ultimate answer must come from
clinical trial in patients with tuberculosis.
Table 2 Pharmacodynamic values of OFX against
M. tuberculosis
Dose
Time 
MIC90*
hour Cmax/MIC90
AUC0–24/
MIC90
600 mg 20 8 61
800 mg 24 9.8 85
* MIC 	 1.0 mg/L.
OFX 	 ofloxacin; MIC 	 minimum inhibitory concentration; Cmax 	 peak
plasma concentration; AUC 	 area under the concentration-time curve.
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R É S U M É
OBJECTIF : Evaluer le profil pharmacocinétique de
l’ofloxacine chez des volontaires sains après des doses
orales uniques de 600 et 800 mg.
SCHÉMA : On a administré à un intervalle d’une semaine
à deux reprises des doses de 600 mg et de 800 mg
d’ofloxacine à sept volontaires bien portants. Des échan-
tillons appariés de sang et de salive ont été prélevés 1, 2,
3, 6, 9, 12, 24, 32 et 48 heures après la prise. Les échan-
tillons d’urines ont été recueillis sur une période de 0–6,
6–12 et 12–24 heures. Les concentrations d’ofloxacine
ont été déterminées par chromatographie liquide de
haute performance dans le plasma, la salive et l’urine.
RÉSULTATS : Avec la dose de 800 mg, on a observé une
augmentation de 20% du pic de concentration plasma-
tique (Cmax) et de 40% de la zone sous la courbe temps-
concentration (AUC0–24). Les autres paramètres, en
l’occurrence la durée nécessaire pour atteindre Cmax, la
demi-vie, le volume apparent de distribution, la clairance
plasmatique et rénale et le pourcentage de la dose
excrété dans les urines sur une période de 24 heures ont
été indépendants des doses. Les ratios moyens de con-
centration dans la salive par rapport au plasma ont été
de 0,4–0,6 et le coefficient de corrélation de 0,94.
CONCLUSIONS : On a observé pour la Cmax et pour la
AUC0–24 une proportionnalité à la dose en administrant
soit 600 soit 800 mg d’ofloxacine. La détermination de
l’ofloxacine dans la salive paraît une méthode valable
pour le suivi thérapeutique du médicament.
R E S U M E N
OBJETIVO : Evaluar el perfil farmacocinético de la ofloxa-
cina en voluntarios sanos después de una dosis única de
600 y 800 mg.
DISEÑO : Se administró 600 y 800 mg de ofloxacina, con
un intervalo de una semana, a 70 voluntarios sanos. Se
recolectaron muestras pareadas de sangre y saliva 1, 2,
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3, 6, 9, 12, 24, 32 y 48 horas después de la adminis-
tración de cada dosis. Se midió la concentración de ofloxa-
cina en el plasma, saliva y orina por cromatografía
líquida de alto rendimiento.
RESULTADOS : Con la dosis de 800 mg se observó un
aumento de 22% de la concentración plasmática má-
xima (Cmax) y de 40% del área bajo la curva tiempo-
concentración (AUC0–24). Los otros parámetros, princi-
palmente el tiempo para alcanzar la Cmax, la vida media, el
volumen aparente de distribución, el clearance plasmático
y renal y el porcentaje de la dosis excretado por la orina
en 24 horas, fueron independientes de la dosis. Los co-
eficientes promedio de concentración en la saliva en re-
lación a la concentración en el plasma fueron de 0,4–0,6
y el coeficiente de correlación fue de 0,94.
CONCLUSIÓN : Se observó una proporcionalidad en la
Cmax y en la AUC0–24 cuando se administraba 600 u 800
mg de ofloxacina. La determinación de la ofloxacina en
la saliva parece ser un método conveniente para el con-
trol terapéutico de la droga.
